Abbott Predicts Humira Will Become $1 Bil. Product In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Adalimumab continues to eat away at Enbrel’s share of the self-injectable rheumatoid arthritis market, accounting for 27% of new prescriptions, up 2.5 points from December, Abbott says.
You may also be interested in...
Celebrex Label Adds Cardiovascular Risk Language
Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.
Celebrex Label Adds Cardiovascular Risk Language
Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.
Enbrel Maxing Out: Wyeth Sees Sales At Top End Of Forecast
Wyeth is "more confident than ever" that Enbrel will be "category leader" for TNF inhibitors, firm says. Enbrel on track for about $1.8 bil. in revenues this year.